Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors

Journal of Clinical Oncology

Volumn 20, Issue 6, 2002, Pages 1657-1667

  Kuenen, Bart C ^a   Rosen, Lee ^a   Smit, Egbert F ^a   Parson, Mandy R N ^a   Levi, Marcel ^a   Ruijter, Rita ^a   Huisman, Holger ^a   Kedde, Marc A ^a   Noordhuis, Paul ^a   Van Der Vijgh, Wim J F ^a   Peters, Godefridus J ^a   Cropp, Gillian F ^a   Scigalla, Paul ^a   Hoekman, Klaus ^a   Pinedo, Herbert M ^a   Giaccone, Giuseppe ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE; SEMAXANIB;

ADULT; AGED; ARTICLE; CELL CYCLE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG EFFICACY; ENDOTHELIUM CELL; FEMALE; HEADACHE; HUMAN; LEUKOPENIA; MALE; NAUSEA; PHASE 1 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA; THROMBOEMBOLISM;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDOLES; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; PYRROLES; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 0037087585     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.6.1657     Document Type: Article

References (68)

1. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
2. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
3. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
4. Angiogenesis in cancer and other diseases
5. Angiogenesis in cancer, vascular, rheumatoid and other disease
6. Angiogenesis as a biologic and prognostic indicator in human breast carcinoma
7. Angiogenesis in malignancies of the female genital tract
8. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma
9. Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus
10. Vascular endothelial growth factor and its receptor correlate with angiogenesis and survival in pulmonary adenocarcinoma
11. Protein tyrosine kinase inhibitors as novel therapeutic agents
12. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent
13. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
14. Vascular endothelial growth factor in human colon cancer: Biology and therapeutic implications
15. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis
16. Phase 1 dose-escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies
17. Pharmacokinetics and pharmacodynamics of SU5416 in a phase I, dose escalating trial in patients with advanced malignancies
18. Results of a phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies
19. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents
20. Barriers to drug delivery in solid tumors
21. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: A phase II study
22. Synergistic interaction between cisplatin and gemcitabine in vitro
23. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines
24. Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors
25. Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients
26. Reporting results of cancer treatment
27. The routine determination of the endogenous thrombin potential, first results in different forms of hyper- and hypocoagulability
28. Performance characteristics of a commercial kit for assay of factor viii-related antigen
29. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: A phase II clinical trial
30. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer
31. Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: A phase II multicenter trial
32. SU5416, a molecularly targeted novel anti-angiogenesis drug: Clinical pharmacokinetics and safety review. 11th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, November 7-10, 2000
33. VEGF nuclear accumulation correlates with phenotypical changes in endothelial cells
34. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor
35. Thrombomodulin-dependent anticoagulant activity is regulated by vascular endothelial growth factor
36. 2+ and von Willebrand factor release in human endothelial cells
37. Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk- 1 receptor and a protein kinase C signaling pathway
38. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells
39. Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor
40. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor- 1 in microvascular endothelial cells
41. Cisplatin triggers platelet activation
42. Increased production of interleukin- 1 and tumor necrosis factor by human monocytes treated in vitro with cisplatin or other biological response modifiers
43. Activation of human peripheral-blood-derived monocytes by cis- diamminedichloroplatinum: Enhanced tumoricidal activity and secretion of tumor necrosis factor-alpha
44. Release of cytokines from human umbilical vein endothelial cells treated with platinum compounds in vitro
45. Endothelial cells in physiology and in the pathophysiology of vascular disorders
46. Vascular-bed-specific hemostasis and hypercoagulable states
47. Deep-vein thrombosis
48. Atherosclerosis
49. Comparative pathology: Radiation-induced coronary artery disease in man and animals
50. Carotid thrombosis following neck irradiation
51. Side effects of chemotherapy: Case I - Radiation recall dermatitis from gemcitabine
52. Side effects of chemotherapy: Case 2 - Radiation recall reaction induced by gemcitabine
53. Side effects of chemotherapy: Case 3 - Acute interstitial pneumonitis related to gemcitabine
54. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy
55. Severe vascular toxicity associated with vinblastine, Neomycin, and cisplatin chemotherapy
56. Acute vascular episodes associated with therapy for carcinomas of the upper aerodigestive tract with bleomycin, vineristine, and cisplatin
57. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis
58. Thromboembolic events during chemotherapy for germ cell cancer: A cohort study and review of the literature
59. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer
60. Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome
61. Neurological complications of radiotherapy and chemotherapy
62. Evaluation of an implantable venous access system in a general oncology population
63. Implantable vascular access systems: Experience in 1500 patients with totally implanted central venous port systems
64. Complications of an implantable venous access device (Port-a-Cath) during intermittent continuous infusion of chemotherapy
65. Continuous infusion of chemotherapy on an outpatient basis via a totally implanted venous access port
66. A phase I/II study of SU5416 in combination with 5-FU/leucovorin in patients with metastatic colorectal cancer
67. A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIb/IV NSCLC
68. A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial growth factor) in patients with relapsed metastatic breast cancer